Pacific Biosciences of California Stock Forecast, Price & News

Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

Is Pacific Biosciences of California a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pacific Biosciences of California stock.
View analyst ratings for Pacific Biosciences of California or view top-rated stocks.

How has Pacific Biosciences of California's stock been impacted by COVID-19 (Coronavirus)?

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PACB shares have increased by 581.1% and is now trading at $23.43.
View which stocks have been most impacted by COVID-19.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Pacific Biosciences of California.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.01. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 29.42% and a negative net margin of 30.39%. During the same quarter last year, the company earned ($0.14) earnings per share.
View Pacific Biosciences of California's earnings history.

What price target have analysts set for PACB?

4 brokers have issued 12-month target prices for Pacific Biosciences of California's stock. Their forecasts range from $41.00 to $62.00. On average, they expect Pacific Biosciences of California's share price to reach $50.00 in the next year. This suggests a possible upside of 113.4% from the stock's current price.
View analysts' price targets for Pacific Biosciences of California or view top-rated stocks among Wall Street analysts.

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the following people:

• Christian O. Henry, President, Chief Executive Officer & Director
• Mark David van Oene, Chief Operating Officer
• Susan G. Kim, Chief Financial Officer (LinkedIn Profile)
• Stephen W. Turner, Chief Technology Officer
• Jonas Korlach, Chief Scientific Officer

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California CEO Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among Pacific Biosciences of California's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacific Biosciences of California's key competitors?

Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Waters (WAT), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of PACB's competitors.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.10%), Sumitomo Mitsui Trust Holdings Inc. (4.69%), Nikko Asset Management Americas Inc. (4.69%), SB Management Ltd (3.70%), Casdin Capital LLC (3.62%) and William Blair Investment Management LLC (2.06%). Company insiders that own Pacific Biosciences of California stock include Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Susan G Kim, Susan K Barnes and William W Ericson.
View institutional ownership trends for Pacific Biosciences of California.

Which institutional investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including SB Management Ltd, Two Sigma Investments LP, Renaissance Technologies LLC, Millennium Management LLC, Goldman Sachs Group Inc., Eagle Asset Management Inc., Cambridge Investment Research Advisors Inc., and Caption Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Susan G Kim, and William W Ericson.
View insider buying and selling activity for Pacific Biosciences of California or view top insider-selling stocks.

Which institutional investors are buying Pacific Biosciences of California stock?

PACB stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Casdin Capital LLC, Farallon Capital Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Pura Vida Investments LLC, Morgan Stanley, and Squarepoint Ops LLC.
View insider buying and selling activity for Pacific Biosciences of California or or view top insider-buying stocks.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $23.43.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California has a market capitalization of $5.17 billion and generates $78.89 million in revenue each year. The biotechnology company earns $29.40 million in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

Pacific Biosciences of California employs 412 workers across the globe.

When was Pacific Biosciences of California founded?

Pacific Biosciences of California was founded in 2004.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is www.pacb.com.

Where are Pacific Biosciences of California's headquarters?

Pacific Biosciences of California is headquartered at 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at (650) 521-8000, via email at [email protected], or via fax at 302-636-5454.